Moteur de recherche d’entreprises européennes
Financement de l’UE (3 948 844 €) : ISOTOPIC LABELING FOR DRUG INNOVATION Hor27/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
ISOTOPIC LABELING FOR DRUG INNOVATION
Excessive attrition rates during clinical trials dramatically impact on Drug Discovery and Development (DDD). Absorption, Distribution, Metabolism and Excretion studies carried out on larger series of drug candidates at an earlier stage of the DDD timeline and evaluation of drug efficacy through better assessment of pharmacokinetic/pharmacodynamic relationships, target engagement and receptor occupancy are critically important approaches for de-risking drug innovation since they facilitate early identification of the candidates that display the best in vivo profile. When successfully implemented, this strategy can accelerate the discovery of new therapeutic solutions to existing and emerging diseases, and enhance European pharmaceutical innovation. For implementation, large sets of isotopically-labeled molecules are required and consequently, a huge revival of labeling techniques is urgently needed. Another crucial issue is the scarcity of expert radiochemists in Europe and the lack of first class training programs in this inter-disciplinary field merging chemistry, radiochemistry and medicinal chemistry. The aims of ISOTOPICS are: i) to train the next generation of European chemists with expertise in isotopic labeling and advanced medicinal chemistry through a first-class taught and research training program combined with a highly interactive secondments plan; ii) to develop innovative and general isotopic labeling chemistry and radiochemistry to streamline the synthesis of labeled small-molecule drugs and biologics; iii) to work closely with the European pharmaceutical industry to apply the new labeling methods to drugs currently in development in order to provide solutions to the most pressing problems in drug innovation. This highly interdisciplinary project is expected to have a profound beneficial impact on drug innovation in Europe by providing novel efficient techniques and new experts in the fields of labeling and medicinal chemistries.
| Instn | ? |
| Astrazeneca AB | 263 659 € |
| Centre National de la Recherche Scientifique CNRS | 262 876 € |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 1 051 502 € |
| Karolinska Institutet | 527 319 € |
| SANOFI-AVENTIS DEUTSCHLAND GmbH | 249 216 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 1 093 152 € |
| UCB Biopharma | 250 560 € |
| UCB Pharma SA | 0,00 € |
| Universite de Liege | 250 560 € |
https://cordis.europa.eu/project/id/675071
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Instn, Saclay.
Les visualisations de "Instn - Financement de l’UE (3 948 844 €) : ISOTOPIC LABELING FOR DRUG INNOVATION"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
